Frontlight ResearchEarly access
CompletedNo phase
Multicenter Clinical Trial of a Phakic Implantable Collamer® Lens (ICL)
Key facts
- Who runs it
- Staar Surgical Company
- Where
- Bowie, Brecksville, Dallas, Draper, Honolulu, Indianapolis, King of Prussia, Omaha, Overland Park, Phoenix, Salt Lake City, San Antonio, Sioux Falls, and St Louis, United StatesSee the 14 sites
- Trial code
- Status
- Completed
- People taking part
- 327 people enrolled
- Started
- 30 Jan 2020
- Ended
- 15 Dec 2023
- Type of study
- Interventional, 2 groups
- Treatments tested
- EVO/EVO+ Visian ICL
- Record updated
- 16 March 2026
Who can take part
- Age
- 21 years to 45 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- Moderate to high myopia or myopic astigmatism correctable with available EVO/EVO+ ICL powers
- Stable refractive history within 0.50 D each cylinder and spherical equivalent (SE) for 1 year prior to implantation
- Able and willing to return for scheduled follow-up examinations after surgery
- Able to read, understand and provide written informed consent on the Institutional Review Board (IRB)-approved informed consent form (ICF) and provide authorization as appropriate for local privacy regulations
- Other protocol-specified inclusion criteria may apply
Who cannot take part
- History of previous ocular surgery
- Insulin-dependent diabetes or diabetic retinopathy
- Cataract of any grade
- Monocular
- Pregnant or nursing women, or those who plan to become pregnant over the course of this clinical study
- Other protocol-specified exclusion criteria may apply
Where in United States
- Solomon Eye Physicians and Surgeons/Bowie Vision InstituteBowie, United States
- Cleveland Eye ClinicBrecksville, United States
- Key-Whitman Eye CenterDallas, United States
- Hoopes Vision/Hoopes, Durrie, Rivera ResearchDraper, United States
- Aloha Laser Vision, LLCHonolulu, United States
- Price Vision GroupIndianapolis, United States
- Kremer Eye CenterKing of Prussia, United States
- Kugler Vision, PCOmaha, United States
- Durrie VisionOverland Park, United States
- Barnett Dulaney PerkinsPhoenix, United States
- The Eye Institute of UtahSalt Lake City, United States
- Parkhurst NuVisionSan Antonio, United States
- Vance Thompson VisionSioux Falls, United States
- Brinton VisionSt Louis, United States
About the trial
What the trial wants to find out
This objective of this study is to evaluate the safety, and to collect supportive data on effectiveness of the EVO/EVO+ Visian® Implantable Collamer® Lens (ICL) in study participants who have a diagnosis of myopia or myopia with astigmatism. Primary study analysis will be evaluated when 300 primary eyes complete 6 months of follow-up. Final study analysis will be assessed when all treated eyes complete 36 months of follow-up.
The 2 groups in the trial
- Primary EyesTreatment being tested
First implanted eyes of enrolled participants
Treatment: EVO/EVO+ Visian ICL
- Fellow EyesTreatment being tested
Second implanted eyes of enrolled participants
Treatment: EVO/EVO+ Visian ICL
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter Clinical Evaluation of the EVO/EVO+ Visian® Implantable Collamer® Lens
- Record updated
- 16 March 2026